- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Following the Patient's Lead
The old adage “the doctor knows best” affirms patients’ trust in a physician’s impartial and expert opinion in matters of health, but can physicians continue to be solo managers of patient care? At Newton Medical Center in Newton, NJ, Renee C. Comizio, M.D., M.S., board-certified plastic and reconstructive surgeon, is providing an avenue for breast cancer patients to take an active role in defining their own treatments through shared decision-making.
The shared decision-making program is founded in the belief that each patient has the right to choose the most appropriate medical treatment for his or her life and medical concern. An informed medical decision ensures safety and personalized care while reducing the chance of treatment being tailored to the physician’s preference rather than the patient’s needs and desires.
Read more at: http://www.mdnews.com/news/2011_12/05782_novdec2011_following-the-patient
Source: MDNews.com
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More
